In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Plus Therapeutics Inc (NASDAQ: PSTV) closed at $0.68 down -9.51% from its previous closing price of $0.75. In other words, the price has decreased by -$9.51 from its previous closing price. On the day, 2.44 million shares were traded. PSTV stock price reached its highest trading level at $0.7249 during the session, while it also had its lowest trading level at $0.6.
Ratios:
For a deeper understanding of Plus Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.44 and its Current Ratio is at 0.44.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on January 25, 2021, initiated with a Buy rating and assigned the stock a target price of $8.
On October 16, 2020, Maxim Group started tracking the stock assigning a Buy rating and target price of $6.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 13 ’24 when Hawkins Richard J bought 4,000 shares for $1.50 per share. The transaction valued at 5,996 led to the insider holds 15,188 shares of the business.
Hawkins Richard J bought 6,285 shares of PSTV for $8,512 on Sep 12 ’24. The Director now owns 11,188 shares after completing the transaction at $1.35 per share. On Sep 11 ’24, another insider, Petersen Greg, who serves as the Director of the company, bought 12,500 shares for $1.35 each. As a result, the insider paid 16,875 and bolstered with 48,921 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PSTV now has a Market Capitalization of 4002428 and an Enterprise Value of 2614430. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.70. Its current Enterprise Value per Revenue stands at 0.457 whereas that against EBITDA is -0.187.
Stock Price History:
The Beta on a monthly basis for PSTV is 0.79, which has changed by -0.60465115 over the last 52 weeks, in comparison to a change of 0.09506309 over the same period for the S&P500. Over the past 52 weeks, PSTV has reached a high of $2.67, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is -39.79%, while the 200-Day Moving Average is calculated to be -52.35%.
Shares Statistics:
For the past three months, PSTV has traded an average of 8.63M shares per day and 50801280 over the past ten days. A total of 5.90M shares are outstanding, with a floating share count of 5.75M. Insiders hold about 2.55% of the company’s shares, while institutions hold 11.50% stake in the company. Shares short for PSTV as of 1740700800 were 140444 with a Short Ratio of 0.02, compared to 1738281600 on 88408. Therefore, it implies a Short% of Shares Outstanding of 140444 and a Short% of Float of 2.4300002000000003.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Plus Therapeutics Inc (PSTV) is currently drawing attention from 4.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.33 and low estimates of -$0.78.
Analysts are recommending an EPS of between -$1.94 and -$2.21 for the fiscal current year, implying an average EPS of -$2.06. EPS for the following year is -$2.1, with 4.0 analysts recommending between -$1.55 and -$3.56.
Revenue Estimates
For the next quarter, 4 analysts are estimating revenue of $1.73M. There is a high estimate of $1.9M for the next quarter, whereas the lowest estimate is $1.5M.
A total of 3 analysts have provided revenue estimates for PSTV’s current fiscal year. The highest revenue estimate was $6.23M, while the lowest revenue estimate was $4.41M, resulting in an average revenue estimate of $5.41M. In the same quarter a year ago, actual revenue was $4.91M
